Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.ZIOP · Entity 8339 | EVP, Chief Financial Officer | January 29, 2020 | January 31, 2020 |
| Spero Therapeutics, Inc.SPRO · Entity 7014 | CEO & President | February 03, 2025 | February 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date January 29, 2020 · Filed January 31, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 80,500 |
Reported balance
After 2020-01-29 transaction · row 1
1 source rowRow 1 · 2020-01-29 · Grant · Acquired 80,500 · Balance 80,500 F1: 26,834 shares shall vest on 12/31/2020 and 26,833 shares shall vest on each of 12/31/2021 and 12/31/2022. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.21 · Expires 2030-01-29 | Direct | 123,900 |
Reported balance
After 2020-01-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-29 · Grant · Acquired 123,900 · Balance 123,900 F2: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019. |
Filing footnotes · ownership attribution and instrument terms
F1: 26,834 shares shall vest on 12/31/2020 and 26,833 shares shall vest on each of 12/31/2021 and 12/31/2022.
F2: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019.
Spero Therapeutics, Inc.
Report date February 03, 2025 · Filed February 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,736,883 |
Ending reported balance
After 2025-02-05 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-02-03 · Grant · Acquired 751,407 · Balance 1,892,216 F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 3, 2026, subject to the Reporting Person's continued service through the applicable vesting date. Row 2 · 2025-02-05 · Sale · Disposed 6,139 · Balance 1,886,077 F2: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2022. Row 3 · 2025-02-05 · Sale · Disposed 42,786 · Balance 1,843,291 F3: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2023. Row 4 · 2025-02-05 · Sale · Disposed 106,408 · Balance 1,736,883 F4: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 3, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
F2: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2022.
F3: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2023.
F4: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2025 Filed Feb 6, 2025 01:31 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 106,408 | $0.78 | $82,998.24 |
DisclosureSEC source: 0000950170-25-014850 · ownership.xml · nonDerivative · entry 4 Shukla Sath · CIK 0001782817 · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,736,883 F4 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2024. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 01:31 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 42,786 | $0.78 | $33,373.08 |
DisclosureSEC source: 0000950170-25-014850 · ownership.xml · nonDerivative · entry 3 Shukla Sath · CIK 0001782817 · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,843,291 F3 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2023. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 01:31 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 6,139 | $0.78 | $4,788.42 |
DisclosureSEC source: 0000950170-25-014850 · ownership.xml · nonDerivative · entry 2 Shukla Sath · CIK 0001782817 · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,886,077 F2 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2022. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 01:31 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 751,407 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-014850 · ownership.xml · nonDerivative · entry 1 Shukla Sath · CIK 0001782817 · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,892,216 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 3, 2026, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 22:36 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 2,757 | $1.35 | $3,721.95 |
DisclosureSEC source: 0000950170-24-101993 · ownership.xml · nonDerivative · entry 1 Shukla Sath · CIK 0001782817 · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,140,809 F1 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on August 26, 2021. Read SEC document |
| August 05, 2024 Filed Aug 6, 2024 23:56 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 17,641 | $1.31 | $23,109.71 |
DisclosureSEC source: 0000950170-24-092170 · ownership.xml · nonDerivative · entry 2 Shukla Sath · CIK 0001782817 · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,143,566 F1 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of RSUs that were granted to the Reporting Person on August 1, 2023 pursuant to a "sell to cover" provision included in each RSU Agreement. Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 23:56 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 14,800 | $1.32 | $19,536.00 |
DisclosureSEC source: 0000950170-24-092170 · ownership.xml · nonDerivative · entry 1 Shukla Sath · CIK 0001782817 · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,161,207 F1 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of RSUs that were granted to the Reporting Person on August 1, 2023 pursuant to a "sell to cover" provision included in each RSU Agreement. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 01:40 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 45,093 | $1.45 | $65,384.85 |
DisclosureSEC source: 0000950170-24-011487 · ownership.xml · nonDerivative · entry 3 Shukla Sath · CIK 0001782817 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,176,007 F4 · kind: The reported transaction is a sale of common stock pursuant to a preexisting 10b5-1 plan upon the vesting of RSUs that were granted to the Reporting Person on February 1, 2022 and February 1, 2023. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 01:40 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 30,901 | $1.37 | $42,334.37 |
DisclosureSEC source: 0000950170-24-011487 · ownership.xml · nonDerivative · entry 2 Shukla Sath · CIK 0001782817 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,221,100 F2 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2022 and February 1, 2023 pursuant to a "sell to cover" provision included in each RSU Agreement. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $1.36 to $1.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 01:40 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 679,501 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-011487 · ownership.xml · nonDerivative · entry 1 Shukla Sath · CIK 0001782817 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,252,001 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 29, 2023 Filed Aug 30, 2023 20:20 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 4,163 | $1.30 | $5,411.90 |
DisclosureSEC source: 0000950170-23-045441 · ownership.xml · nonDerivative · entry 2 Shukla Sath · CIK 0001782817 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 572,500 F2 · kind: The reported transaction is a sale of common stock pursuant to a preexisting 10b5-1 plan upon the vesting of RSUs that were granted to the Reporting Person on August 26, 2021. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 20:20 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 1,854 | $1.26 | $2,336.04 |
DisclosureSEC source: 0000950170-23-045441 · ownership.xml · nonDerivative · entry 1 Shukla Sath · CIK 0001782817 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 576,663 F1 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") that were granted to the Reporting Person on August 26, 2021 pursuant to a "sell to cover" provision included in the RSU Agreement. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:10 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 266,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-037973 · ownership.xml · nonDerivative · entry 1 Shukla Sath · CIK 0001782817 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 578,517 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 1, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 02, 2023 Filed Feb 4, 2023 00:41 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 9,504 | $1.83 | $17,372.36 |
DisclosureSEC source: 0000899243-23-003945 · doc4.xml · nonDerivative · entry 2 Shukla Sath · CIK 0001782817 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,517 F3 · kind: The reported transaction is a sale of common stock pursuant to a preexisting 10b5-1 plan upon the vesting of RSUs that were granted to the Reporting Person on February 1, 2022. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $1.81 to $1.86 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F2 · balance_after: Includes 312,518 RSUs held by the Reporting Person. Read SEC document |
| February 01, 2023 Filed Feb 4, 2023 00:41 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 265,957 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-003945 · doc4.xml · nonDerivative · entry 1 Shukla Sath · CIK 0001782817 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,021 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2024, subject to the Reporting Person's continued service through the applicable vesting date. F2 · balance_after: Includes 312,518 RSUs held by the Reporting Person. Read SEC document |
| August 29, 2022 Filed Aug 30, 2022 21:00 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 6,017 | $0.89 | $5,377.99 |
DisclosureSEC source: 0000899243-22-030087 · doc4.xml · nonDerivative · entry 1 Shukla Sath · CIK 0001782817 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,064 F1 · kind: The reported transaction is a sale of common stock pursuant to a preexisting 10b5-1 plan upon the vesting on August 26, 2022 of a portion of restricted stock units ("RSUs") granted to the Reporting Person on August 26, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $0.8839 to $0.9002 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F3 · balance_after: Consists of RSUs. Each RSU represents the right to receive one share of common stock upon vesting. 18,050 of the RSUs vest in three equal annual installments beginning on August 26, 2023 and 38,014 of the RSUs vest in four equal annual installments beginning on February 1, 2023, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:19 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 53,190 | $0.00 Strike: $11.18 | $0.00 |
DisclosureSEC source: 0000899243-22-004593 · doc4.xml · derivative · entry 2 Shukla Sath · CIK 0001782817 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,190 Underlying: Common Stock · 53,190 shares Expires 2032-02-01 F3 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:19 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 38,014 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-004593 · doc4.xml · nonDerivative · entry 1 Shukla Sath · CIK 0001782817 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,081 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continued service through the applicable vesting date. F2 · balance_after: Consists of 62,081 RSUs held by the Reporting Person. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 20:15 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 24,067 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-034498 · doc4.xml · nonDerivative · entry 1 Shukla Sath · CIK 0001782817 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,067 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 26, 2022, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:20 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $17.93 | $0.00 |
DisclosureSEC source: 0000899243-21-000366 · doc4.xml · derivative · entry 1 Shukla Sath · CIK 0001782817 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-01-04 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on January 4, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting dates. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:52 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 123,900 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-20-005789 · doc4.xml · derivative · entry 2 Shukla Sath · CIK 0001782817 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,900 Underlying: Common Stock · 123,900 shares Expires 2030-01-29 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:52 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 80,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005789 · doc4.xml · nonDerivative · entry 1 Shukla Sath · CIK 0001782817 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,500 F1 · shares: 26,834 shares shall vest on 12/31/2020 and 26,833 shares shall vest on each of 12/31/2021 and 12/31/2022. Read SEC document |
| July 22, 2019 Filed Jul 24, 2019 12:57 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantEmployee Stock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-19-042993 · doc4.xml · derivative · entry 1 Shukla Sath · CIK 0001782817 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-07-22 F1 · derivative.exercise_date: 100,000 shares subject to the option shall vest on 7/22/2020; 25,000 shares subject to the option shall vest on a quarterly basis thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.